- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05233891
Validation of Scales in Reconstructive Breast Surgery (ValPlast)
June 30, 2025 updated by: Vastra Gotaland Region
The main purpose of the project is to validate patient reported outcomes measures (PROMs) in reconstructive breast surgery.
BREAST-Q will be evaluated for Swedish and Sweden.Hospital Anxiety and Depression Scale (HADS), EuroQol 5D (EQ5D), and SF-36 will be validated for reconstructive breast surgery.
In addition, the complication classification system according to Clavien-Dindo will be validated for reconstructive breast surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emma Hansson, MD, PhD
- Phone Number: +46313421000
- Email: emma.em.hansson@vgregion.se
Study Locations
-
-
-
Gothenburg, Sweden, 413 45
- Recruiting
- Sahlgrenska University Hospital
-
Contact:
- Emma Hansson, PhD
- Phone Number: +46 31 342 10 00
- Email: emma.hansson.2@gu.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Women who will have or have had reconstructive breast surgery.
Description
Inclusion Criteria:
- Women who have had or will have reconstructive breast surgery in Sahlgrenska university hospital.
Exclusion Criteria:
- Do not understand Swedish.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast reconstruction after breast cancer
Women who have had/have breast cancer and will have/have had a breast reconstruction.
|
Breast reconstruction after breast cancer.
|
|
Breast reduction
Women who have had/will have a breast reduction due to breast hypertrophy.
|
Breast reduction due to breast hypertrophy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Validation and reliability of BREAST-Q for Sweden
Time Frame: Pre-operatively
|
Breast-Q measures breast related quality of life on a scale 1-100.
A higher score indicates a higher quality of life.
|
Pre-operatively
|
|
Validation and reliability of BREAST-Q for Sweden
Time Frame: 5 years postoperatively
|
Breast-Q measures breast related quality of life on a scale 1-100.
A higher score indicates a higher quality of life.
|
5 years postoperatively
|
|
Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery
Time Frame: Pre-operatively
|
EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare.
A total score between 0 and 1 is calculated.
Zero equals death and 1 perfect health.
|
Pre-operatively
|
|
Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery
Time Frame: 5 years postoperatively
|
EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare.
A total score between 0 and 1 is calculated.
Zero equals death and 1 perfect health.
|
5 years postoperatively
|
|
Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery
Time Frame: Pre-operatively
|
The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3).
It is designed to measure anxiety and depression (7 items for each subscale).
The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).
|
Pre-operatively
|
|
Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery
Time Frame: 5 years postoperatively
|
The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3).
It is designed to measure anxiety and depression (7 items for each subscale).
The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).
|
5 years postoperatively
|
|
Validation and reliability of RAND-36 for reconstructive breast surgery
Time Frame: Pre-operatively
|
It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales.
Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale.
A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.
|
Pre-operatively
|
|
Validation and reliability of RAND-36 for reconstructive breast surgery
Time Frame: 5 years postoperatively
|
It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales.
Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale.
A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.
|
5 years postoperatively
|
|
Validation of Clavion-Dindo classification for reconstructive breast surgery
Time Frame: 5 years postoperatively
|
The Clavien-Dindo system is based on ranking the severity of the intervention required to treat a given complication, as follows: grade I includes deviations from the postoperative course without the need for pharmacological treatment or surgical/endoscopic/radiological intervention; grade II complications require pharmacological treatment, blood transfusion, or total parental nutrition; grade III complications require surgical/endoscopic/radiological intervention; grade IV includes life-threatening complications, including those involving the central nervous system, that require intensive care treatment; and grade V includes complications that result in death.
|
5 years postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Weick L, Brorson F, Jepsen C, Liden M, Jensen EW, Hansson E. Giving meaning to patient reported outcomes in breast reconstruction after mastectomy - A systematic review of available scores and suggestions for further research. Breast. 2022 Feb;61:91-97. doi: 10.1016/j.breast.2021.11.008. Epub 2021 Nov 25.
- Kamya L, Hansson E, Weick L, Hansson E. Validation and reliability testing of the Breast-Q latissimus dorsi questionnaire: cross-cultural adaptation and psychometric properties in a Swedish population. Health Qual Life Outcomes. 2021 Jul 3;19(1):174. doi: 10.1186/s12955-021-01812-x.
- Weick L, Grimby-Ekman A, Lunde C, Hansson E. Validation and reliability testing of the BREAST-Q expectations questionnaire in Swedish. J Plast Surg Hand Surg. 2023 Feb-Dec;57(1-6):315-323. doi: 10.1080/2000656X.2022.2070180. Epub 2022 May 9.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 21, 2021
Primary Completion (Estimated)
December 21, 2027
Study Completion (Estimated)
December 21, 2027
Study Registration Dates
First Submitted
January 23, 2022
First Submitted That Met QC Criteria
February 9, 2022
First Posted (Actual)
February 10, 2022
Study Record Updates
Last Update Posted (Actual)
July 3, 2025
Last Update Submitted That Met QC Criteria
June 30, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-03165
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Breast reconstruction
-
Vastra Gotaland RegionRecruitingBreast Cancer | Weight Loss | Breast Reconstruction | Surgical Complication | Bariatric Surgery | Breast Implant Infection | Breast Implant | MastopexySweden
-
The Netherlands Cancer InstituteMaastricht University Medical Center; Erasmus Medical Center; Ziekenhuisgroep... and other collaboratorsEnrolling by invitationAutoimmune Diseases | Breast Cancer | Breast Implant; ComplicationsNetherlands
-
Case Comprehensive Cancer CenterWithdrawnBreast Cancer | Malignant Neoplasm of BreastUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Case Comprehensive Cancer CenterWithdrawnBreast Reconstruction | MastectomyUnited States
-
Chang Gung Memorial HospitalActive, not recruitingBreast Reconstruction | Breast Cancer Patients | Nipple-sparing MastectomyTaiwan
-
Memorial Sloan Kettering Cancer CenterWithdrawnBreast ReconstructionUnited States
-
Odense University HospitalSykehuset Telemark; Sygehus LillebaeltUnknownBreast ReconstructionDenmark, Norway
-
University of ManitobaKeeping Abreast CharityCompletedDIEP Flap Breast Reconstruction | SIEA Flap Breast ReconstructionCanada
-
Euromi BiosciencesRecruitingBreast Implant Rupture | Breast Implant; ComplicationsFrance